Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$20.50M+1047.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen L. Silvestro
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 133
- Beta
- 1.09
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.37
Financials
Revenue
$20.50M+1048.0%Net Income
$-703.0KEBITDA
$1.09MFree Cash Flow
$8.58M+109078.9%EPS (diluted)
$-0.04Shares Outstanding (diluted)
18.79M+91.5%Operating Expenses
$12.50MCash & Debt
$24.10MReturn of Capital
$0.00Revenue by Segment (annual)
$215.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $109.43M | $5.13M | $0.28 |
| 2024 | $92.13M | $-20.11M | $-1.10 |
| 2023 | $71.52M | $-17.57M | $-1.03 |
| 2022 | $62.45M | $-11.44M | $-0.64 |
| 2021 | $61.29M | $378.1K | $0.02 |
| 2020 | $43.31M | $-2.21M | $-0.15 |
| 2019 | $24.60M | $-3.14M | $-0.23 |
| 2018 | $21.21M | $226.3K | $0.02 |
| 2017 | $12.13M | $-2.10M | $-0.21 |
| 2016 | $7.75M | $-1.54M | $-0.16 |
| 2015 | $7.22M | $-595.1K | $-0.07 |
| 2014 | $6.50M | $-1.03M | $-0.14 |
| 2013 | $4.96M | $215.8K | $-0.06 |
| 2012 | $2.05M | $-364.0K | $-0.08 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.41
- Implied price
- $17.88
- Return from $8.57
- 15.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.89 — today's price is already 3.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 30 | 37 | 44 | 51 | 58 |
|---|---|---|---|---|---|
| -2.0% | -2.6% | 1.5% | 5.1% | 8.3% | 11.1% |
| 3.0% | 2.3% | 6.7% | 10.5% | 13.8% | 16.8% |
| 8.0% | 7.3% | 11.9% | 15.8% | 19.3% | 22.4% |
| 13.0% | 12.3% | 17.1% | 21.2% | 24.8% | 28.1% |
| 18.0% | 17.2% | 22.3% | 26.6% | 30.4% | 33.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70-54.84%Social Signal Score
Mentions (10)
- Newszacks.com·12d ago·Positive
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars? The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
View source ↗ - Newsglobenewswire.com·14d ago·Positive
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making OptimizeRx's authenticated point of care inventor…
View source ↗ - Newsseekingalpha.com·18d ago·Positive
OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings. OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow
View source ↗ - Newsglobenewswire.com·28d ago·Positive
… Participate in the 10th Annual Lake Street Best Ideas Growth Conference WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced that management will participate in the 10th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 10, …
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Troy Sarich as a Company advisor.
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
OptimizeRx Q2 Earnings Call Highlights OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·54d ago·Positive
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance – Q2 revenue totals $20.5 million– Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively– Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million– Completed debt refinancing with $35 million traditional banking facility, including $25 million term loan and $10 million undrawn revolver; repaid $8.3 million of prin
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.18 per share
Typical surprise +172.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$0.16 vs $0.11beat
- Tue, May 12$0.14 vs $0.01beat
- Thu, Mar 5$0.51 vs $0.23beat
- Thu, Nov 6$0.20 vs $0.03beat
- Thu, Aug 7$0.24 vs $0.03beat
- Mon, May 12$0.08 vs $-0.11beat
Estimates and results for OPRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OPRX officers and directors.
- Bought
- $2.4m
- Sold
- $244k
1 trade
3 trades
- Stelmakh Edwardsold
- Silvestro Stephen Lsold
- Spangler Patrick Dsold
- Lang James Paulbought
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OPRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.